-
Mind Your Mouth: Huntington’s Disease and Oral Health
Latest News
-
DNA Repair in Huntington’s Disease: Not Up to Par?
Genetic mutations occur everyday in our cells, but the vast majority of them are repaired. New research finds DNA repair is not on PAR in HD cells, causing mutations to build up in people with HD.
-
Update on the PTC Therapeutics PIVOT-HD Trial
Last week, PTC Therapeutics released a statement sharing that recruitment of participants into the US arm of the PIVOT-HD trial has been paused. In this article, we will lay out exactly what is known and what this announcement means.
-
Forward momentum for Roche and Wave in latest news about huntingtin-lowering trials
Two companies developing medicines for Huntington’s disease announced news about their huntingtin-lowering drugs. Let’s talk about the history and the caveats surrounding these hopeful pieces of news.
-
Focusing in on fibrils; scientists give us a glimpse of huntingtin protein clumps
Scientists have used powerful microscopes to look at sticky fragments of the Huntington’s disease protein, shedding light on these structures which are thought to drive the disease
-
Hereditary Disease Foundation (HDF) conference 2022 – Day 4
Read updates from clinical trials and scientific research on Huntington’s disease from Day 4 of the 2022 HDF Milton Wexler Biennial Symposium #HDF2022
-
Hereditary Disease Foundation (HDF) conference 2022 – Day 3
Read updates from clinical trials and scientific research on Huntington’s disease from Day 3 of the 2022 HDF Milton Wexler Biennial Symposium #HDF2022
-
Hereditary Disease Foundation (HDF) conference 2022 – Day 2
Read updates from clinical trials and scientific research on Huntington’s disease from Day 2 of the 2022 HDF Milton Wexler Biennial Symposium #HDF2022
-
Hereditary Disease Foundation (HDF) conference 2022 – Day 1
Read updates from clinical trials and scientific research on Huntington’s disease from Day 1 of the 2022 HDF Milton Wexler Biennial Symposium #HDF2022
-
Serious side effects reported for some people treated with the huntingtin-lowering drug AMT-130, currently in clinical trials
After receiving a high dose of uniQure’s gene therapy for Huntington’s disease, a few patients experienced serious side effects, but are now recovering. HDBuzz explores what this means for the experimental huntingtin-lowering drug, AMT-130.
-
Sad news from Novartis: dosing suspended in VIBRANT-HD trial of branaplam
HDBuzz is saddened to share the news that the VIBRANT-HD trial of the oral huntingtin-lowering drug, branaplam, has been temporarily suspended for the safety of participants.
-
Updates from uniQure about their gene therapy for Huntington's disease
uniQure is conducting safety trials of the first gene therapy for HD. A recent press release provided a 1 year update on the first group of 10 people who underwent surgery to receive this experimental drug. Let’s talk more about what it means.